

Barbara Leuchs

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/935924/publications.pdf>

Version: 2024-02-01

25
papers

987
citations

623734

14
h-index

642732

23
g-index

25
all docs

25
docs citations

25
times ranked

1464
citing authors

#	ARTICLE	IF	CITATIONS
1	THER-01. Precision brain tumor therapy by AAV-mediated oncogene editing. <i>Neuro-Oncology</i> , 2022, 24, i185-i186.	1.2	0
2	Human Retrotransposons and the Global Shutdown of Homeostatic Innate Immunity by Oncolytic Parvovirus H-1PV in Pancreatic Cancer. <i>Viruses</i> , 2021, 13, 1019.	3.3	2
3	Phase 2 Trial of Oncolytic H-1 Parvovirus Therapy Shows Safety and Signs of Immune System Activation in Patients With Metastatic Pancreatic Ductal Adenocarcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 5546-5556.	7.0	22
4	Temporal multi-omics identifies LRG1 as a vascular niche instructor of metastasis. <i>Science Translational Medicine</i> , 2021, 13, eabe6805.	12.4	36
5	Upstream process optimization and micro- and macrocarrier screening for large-scale production of the oncolytic H-1 protoparvovirus. <i>Applied Microbiology and Biotechnology</i> , 2021, 105, 9113-9124.	3.6	3
6	Fluorescence In Situ Hybridization (FISH) Detection of Viral Nucleic Acids in Oncolytic H-1 Parvovirus-Treated Human Brain Tumors. <i>Methods in Molecular Biology</i> , 2020, 2058, 295-306.	0.9	0
7	Various effects of AAV9-mediated \hat{I}^2 ARKct gene therapy on the heart in dystrophin-deficient (mdx) mice and \hat{I} -sarcoglycan-deficient (Sgcd ^{-/-}) mice. <i>Neuromuscular Disorders</i> , 2019, 29, 231-241.	0.6	10
8	Preclinical Testing of an Oncolytic Parvovirus in Ewing Sarcoma: Protoparvovirus H-1 Induces Apoptosis and Lytic Infection In Vitro but Fails to Improve Survival In Vivo. <i>Viruses</i> , 2018, 10, 302.	3.3	9
9	A novel scalable, robust downstream process for oncolytic rat parvovirus: isoelectric point-based elimination of empty particles. <i>Applied Microbiology and Biotechnology</i> , 2017, 101, 3143-3152.	3.6	10
10	Oncolytic H-1 Parvovirus Shows Safety and Signs of Immunogenic Activity in a First Phase I/IIa Glioblastoma Trial. <i>Molecular Therapy</i> , 2017, 25, 2620-2634.	8.2	199
11	Protocol for Efficient Generation and Characterization of Adeno-Associated Viral Vectors. <i>Human Gene Therapy Methods</i> , 2017, 28, 235-246.	2.1	44
12	A Hepatic GAbp-AMPK Axis Links Inflammatory Signaling to Systemic Vascular Damage. <i>Cell Reports</i> , 2017, 20, 1422-1434.	6.4	7
13	Preclinical Testing of an Oncolytic Parvovirus: Standard Protoparvovirus H-1PV Efficiently Induces Osteosarcoma Cell Lysis In Vitro. <i>Viruses</i> , 2017, 9, 301.	3.3	16
14	A non-controlled, single arm, open label, phase II study of intravenous and intratumoral administration of ParvOryx in patients with metastatic, inoperable pancreatic cancer: ParvOryx02 protocol. <i>BMC Cancer</i> , 2017, 17, 576.	2.6	36
15	Pediatric and Adult High-Grade Glioma Stem Cell Culture Models Are Permissive to Lytic Infection with Parvovirus H-1. <i>Viruses</i> , 2016, 8, 138.	3.3	19
16	Moving oncolytic viruses into the clinic: clinical-grade production, purification, and characterization of diverse oncolytic viruses. <i>Molecular Therapy - Methods and Clinical Development</i> , 2016, 3, 16018.	4.1	83
17	Standardized large-scale H-1PV production process with efficient quality and quantity monitoring. <i>Journal of Virological Methods</i> , 2016, 229, 48-59.	2.1	12
18	Pathology, organ distribution, and immune response after single and repeated intravenous injection of rats with clinical-grade parvovirus H1. <i>Comparative Medicine</i> , 2015, 65, 23-35.	1.0	12

#	ARTICLE	IF	CITATIONS
19	Bioavailability, biodistribution, and CNS toxicity of clinical-grade parvovirus H1 after intravenous and intracerebral injection in rats. <i>Comparative Medicine</i> , 2015, 65, 36-45.	1.0	12
20	Phase I/IIa study of intratumoral/intracerebral or intravenous/intracerebral administration of Parvovirus H-1 (ParvOryx) in patients with progressive primary or recurrent glioblastoma multiforme: ParvOryx01 protocol. <i>BMC Cancer</i> , 2012, 12, 99.	2.6	134
21	Interferon β improves the vaccination potential of oncolytic parvovirus H-1PV for the treatment of peritoneal carcinomatosis in pancreatic cancer. <i>Cancer Biology and Therapy</i> , 2011, 12, 888-895.	3.4	33
22	Regression of Glioma in Rat Models by Intranasal Application of Parvovirus H-1. <i>Clinical Cancer Research</i> , 2011, 17, 5333-5342.	7.0	31
23	Parvovirus H1 selectively induces cytotoxic effects on human neuroblastoma cells. <i>International Journal of Cancer</i> , 2010, 127, 1230-1239.	5.1	36
24	Improvement of Gemcitabine-Based Therapy of Pancreatic Carcinoma by Means of Oncolytic Parvovirus H-1PV. <i>Clinical Cancer Research</i> , 2009, 15, 511-519.	7.0	84
25	Improved cardiac gene transfer by transcriptional and transductional targeting of adeno-associated viral vectors. <i>Cardiovascular Research</i> , 2006, 70, 70-78.	3.8	137